A Review of Clinical Studies Assessing the Therapeutic Efficacy of Escitalopram: A Step Towards Development.

Vishal Bhatia, Ashwani K Dhingra, Bhawna Chopra, Kumar Guarve

CNS & neurological disorders drug targets 2023

filter terms:

Major depression is a debilitating, sometimes fatal disorder, deteriorating the quality of life and well-being. Escitalopram showed highly selective and dose-dependent inhibitory activity on human serotonin transport. Selective serotonin reuptake inhibitors (SSRIs) are the first-line drugs to manage major depressive disorder (MDD). The objective of this study is to explore the therapeutic potential of escitalopram, a clinically approved drug to manage MDD and panic disorders. It emphasizes comparative and clinical trial studies with several pharmacological targets reviewed from the data available on PubMed, Science Direct, Clinicaltrails.gov, and from many reputed foundations. To highlight the clinical efficacy, safety, recent development, and stable formulation of escitalopram with an increased bioavailability profile. Evidence-based on the available clinical and pharmacoeconomic data, escitalopram represents an effective first-line treatment option for MDD patients. The present review highlights the placebo-controlled clinical studies and the recent development that can be helpful for further research perspectives. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Citation

Vishal Bhatia, Ashwani K Dhingra, Bhawna Chopra, Kumar Guarve. A Review of Clinical Studies Assessing the Therapeutic Efficacy of Escitalopram: A Step Towards Development. CNS & neurological disorders drug targets. 2023;22(1):41-50